1932

Abstract

Public health authorities have described, with growing alarm, an unprecedented increase in morbidity and mortality associated with use of opioid pain relievers (OPRs). Efforts to address the opioid crisis have focused mainly on reducing nonmedical OPR use. Too often overlooked, however, is the need for preventing and treating opioid addiction, which occurs in both medical and nonmedical OPR users. Overprescribing of OPRs has led to a sharp increase in the prevalence of opioid addiction, which in turn has been associated with a rise in overdose deaths and heroin use. A multifaceted public health approach that utilizes primary, secondary, and tertiary opioid addiction prevention strategies is required to effectively reduce opioid-related morbidity and mortality. We describe the scope of this public health crisis, its historical context, contributing factors, and lines of evidence indicating the role of addiction in exacerbating morbidity and mortality, and we provide a framework for interventions to address the epidemic of opioid addiction.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-publhealth-031914-122957
2015-03-18
2024-04-13
Loading full text...

Full text loading...

/deliver/fulltext/publhealth/36/1/annurev-publhealth-031914-122957.html?itemId=/content/journals/10.1146/annurev-publhealth-031914-122957&mimeType=html&fmt=ahah

Literature Cited

  1. Angres DH, Bettinardi-Angres K. 1.  2008. The disease of addiction: origins, treatment, and recovery. Dis. Mon. 54:696–721 [Google Scholar]
  2. Angst MS, Clark JD. 2.  2006. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 104:570–87 [Google Scholar]
  3. Arria AM, Caldeira KM, Vincent KB, O'Grady KE, Wish ED. 3.  2008. Perceived harmfulness predicts nonmedical use of prescription drugs among college students: interactions with sensation-seeking. Prev. Sci. 9:191–201 [Google Scholar]
  4. Blackwell DL, Lucas JW, Clarke TC. 4.  2014. Summary Health Statistics for U.S. Adults: National Health Interview Survey, 2012. Vital Health Stat. 10(260). Hyattsville, MD: Natl. Cent. Health Stat., U.S. Dept. Health Hum. Serv.
  5. Blair T. 5.  1919. Is opium the “sheet-anchor of treatment”?. Am. J. Clin. Med. 26:829–34 [Google Scholar]
  6. Boscarino JA, Rukstalis M, Hoffman SN, Han JJ, Erlich PM. 6.  et al. 2010. Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. Addiction 105:1776–82 [Google Scholar]
  7. Boscarino JA, Rukstalis MR, Hoffman SN, Han JJ, Erlich PM. 7.  et al. 2011. Prevalence of prescription opioid-use disorder among chronic pain patients: comparison of the DSM-5 versus DSM-4 diagnostic criteria. J. Addict. Dis. 30:185–94 [Google Scholar]
  8. Boudreau D, Von Korff M, Rutter CM, Saunders K, Ray GT. 8.  et al. 2009. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol. Drug Saf. 18:1166–75 [Google Scholar]
  9. Campbell JN. 9.  1996. APS 1995 presidential address. Pain Forum 5:85–88 [Google Scholar]
  10. 10. CDC (Cent. Dis. Control Prev.) 2011. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR 60:1487–92 [Google Scholar]
  11. 11. CDC (Cent. Dis. Control Prev.) 2012. Community-based opioid overdose prevention programs providing naloxone—United States, 2010. MMWR 6:101–5 [Google Scholar]
  12. 12. CDC (Cent. Dis. Control Prev.) 2013. Vital signs: overdoses of prescription opioid pain relievers and other drugs among women—United States, 1999–2010. MMWR 62:537–42 [Google Scholar]
  13. 13. CDC (Cent. Dis. Control Prev.) 2014. CDC's Top Ten: 5 Health Achievements in 2013 and 5 Health Threats in 2014. Atlanta, GA: CDC http://blogs.cdc.gov/cdcworksforyou24-7/2013/12/cdc's-top-ten-5-health-achievements-in-2013-and-5-health-threats-in-2014/
  14. 14. CDC (Cent. Dis. Control Prev.) 2014. QuickStats: rates of drug poisoning deaths involving heroin,* by selected age and racial/ethnic groups—United States, 2002 and 2011. MMWR 63:595 [Google Scholar]
  15. Chen LH, Hedegaard H, Warner M. 15.  2014. Drug-Poisoning Deaths Involving Opioid Analgesics: United States, 1999–2011 NCHS Data Brief No. 166. Hyattsville, MD: Natl. Cent. Health Stat.
  16. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. 16.  2014. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry 71:821–26 [Google Scholar]
  17. Comer SD, Sullivan MA, Whittington RA, Vosburg SK, Kowalczyk WJ. 17.  2008. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology 33:1179–91 [Google Scholar]
  18. Courtwright DT. 18.  2001. Dark Paradise: A History of Opiate Addiction in America Cambridge, MA: Harvard Univ. Press Revis. ed.
  19. Coyle MG, Salisbury AL, Lester BM, Jones HE, Lin H. 19.  et al. 2012. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction 107:63–73 [Google Scholar]
  20. Daubresse M, Chang HY, Yu Y, Viswanathan S, Shah ND. 20.  et al. 2013. Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000–2010. Med. Care 51:870–78 [Google Scholar]
  21. Davis CS, Ruiz S, Glynn P, Picariello G, Walley AY. 21.  2014. Expanded access to naloxone among firefighters, police officers, and emergency medical technicians in Massachusetts. Am. J. Public Health 104:e7–9 [Google Scholar]
  22. Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Beatrice S. 22.  et al. 2005. HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. Am. J. Public Health 95:1439–44 [Google Scholar]
  23. Digiusto E, Shakeshaft A, Ritter A, O'Brien S, Mattick RP. 23.  2004. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence. Addiction 99:450–60 [Google Scholar]
  24. DuPont RL, Greene MH. 24.  1973. The dynamics of a heroin addiction epidemic. Science 181:716–22 [Google Scholar]
  25. Eriksen J, Sjøgren P, Bruera E, Ekholm O, Rasmussen NK. 25.  2006. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain 125:172–79 [Google Scholar]
  26. Fareed A, Vayalapalli S, Byrd-Sellers J, Casarella J, Drexler K. 26.  2011. Safety and efficacy of long-term buprenorphine maintenance treatment. Addict. Dis. Treat. 10:123–30 [Google Scholar]
  27. Fauber J. 27.  2012. Painkiller boom fueled by networking: doctors, researchers with financial ties to drug makers set stage for surge in prescriptions. Milwaukee-Wisconsin Journal Sentinel Feb. 18, p. A1
  28. Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. 28.  2008. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 9:444–59 [Google Scholar]
  29. Franklin GM. 29.  2014. Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology. Neurology 83:1277–84 [Google Scholar]
  30. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN. 30.  et al. 2003. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N. Engl. J. Med. 349:949–58 [Google Scholar]
  31. Haddox JD, Joranson D, Angarola RT, Brady A, Carr DB. 31.  et al. 1997. The use of opioids for the treatment of chronic pain: a consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin. J. Pain 13:6–8 [Google Scholar]
  32. Hagan H, Pouget ER, Williams IT, Garfein RL, Strathdee SA. 32.  et al. 2010. Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. J. Infect. Dis. 201:378–85 [Google Scholar]
  33. Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC. 33.  et al. 2008. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 300:2613–20 [Google Scholar]
  34. Herzig SJ, Rothberg MB, Cheung M, Ngo LH, Marcantonio ER. 34.  2014. Opioid utilization and opioid-related adverse events in nonsurgical patients in US hospitals. J. Hosp. Med. 9:73–81 [Google Scholar]
  35. Hopkins D, Dreyzehner JJ, O'Leary T. 35.  2014. Lessons learned from mandating prescriber compliance Presented at Natl. Prescr. Abuse Sum., April 22–23, Atlanta
  36. Hser YI, Hoffman V, Grella CE, Anglin MD. 36.  2001. A 33-year follow-up of narcotics addicts. Arch. Gen. Psychiatry 58:503–8 [Google Scholar]
  37. Hughes PH, Barker NW, Crawford GA, Jaffe JH. 37.  1972. The natural history of a heroin epidemic. Am. J. Public Health 62:995–1001 [Google Scholar]
  38. 38. INCB (Int. Narc. Control Board) 2007. The Report of the International Narcotics Control Board for 2007 Vienna: INCB
  39. Johnson EM, Lanier WA, Merrill RM, Crook J, Porucznik CA. 39.  et al. 2013. Unintentional prescription opioid-related overdose deaths: description of decedents by next of kin or best contact, Utah, 2008–2009. J. Gen. Intern. Med. 28:522–29 [Google Scholar]
  40. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. 40.  2000. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N. Engl. J. Med. 343:1290–97 [Google Scholar]
  41. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. 41.  2014. Monitoring the future National Survey Results on Drug Use: 1975–2013. Overview, key findings on adolescent drug use. Ann Arbor, MI: Inst. Soc. Res., Univ. Mich.
  42. Jones CM. 42.  2013. Trends in the distribution of selected opioids by state, US, 1999–2011 Presented at Natl. Meet. Safe States Alliance, June 6, Baltimore, MD
  43. Jones CM, Paulozzi LJ, Mack KA. 43.  2014. Sources of prescription opioid pain relievers by frequency of past-year nonmedical use: United States, 2008–2011. JAMA Intern. Med. 174:802–3 [Google Scholar]
  44. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG. 44.  et al. 2010. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N. Engl. J. Med. 363:2320–31 [Google Scholar]
  45. Juurlink DN, Dhalla IA. 45.  2012. Dependence and addiction during chronic opioid therapy. J. Med. Toxicol. 8:393–99 [Google Scholar]
  46. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 46.  2003. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 361:662–68 [Google Scholar]
  47. Katz N, Dart RC, Bailey E, Trudeau J, Osgood E, Paillard F. 47.  2011. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am. J. Drug Alcohol Abuse 37:205–17 [Google Scholar]
  48. Kreiner P, Nikitin R, Shields TP. 48.  2014. Bureau of Justice Assistance Prescription Drug Monitoring Program Performance Measures Report: January 2009 through June 2012 Waltham, MA: PDMP Cent. Excell., Brandeis Univ.
  49. Ling W, Charuvastra C, Collins JF, Batki S, Brown LS. 49.  et al. 1998. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 93:475–86 [Google Scholar]
  50. Martell BA, O'Connor PG, Kerns RD, Becker WC, Morales KH. 50.  et al. 2007. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann. Intern. Med. 146:116–27 [Google Scholar]
  51. McCarthy JJ, Leamon MH, Parr MS, Anania B. 51.  2005. High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. Am. J. Obstet. Gynecol. 193:606–10 [Google Scholar]
  52. Medina JL, Diamond S. 52.  1977. Drug dependency in patients with chronic headache. Headache 17:12–14 [Google Scholar]
  53. Monte AA, Heard KJ, Hoppe JA, Vasiliou V, Gonzalez FJ. 53.  2015. The accuracy of self-reported drug ingestion histories in emergency department patients. J. Clin. Pharmacol. 5533–38
  54. Muhuri PK, Gfroerer JC, Davies MC. 54.  2013. Associations of nonmedical pain reliever use and initiation of heroin use in the United States. CBHSQ Data Rev Aug.: http://www.samhsa.gov/data/sites/default/files/DR006/DR006/nonmedical-pain-reliever-use-2013.htm
  55. 55. N.Y. City Dep. Health Ment. Hyg 2013. New York City Emergency Department Discharge Opioid Prescribing Guidelines Long Island City, NY: NYC Health. http://www.nyc.gov/html/doh/downloads/pdf/basas/opioid-prescribing-guidelines.pdf
  56. Owens PL, Barrett ML, Weiss AJ, Washington RE, Kronick R. 56.  2014. Hospital inpatient utilization related to opioid overuse among adults, 1993–2012 HCUP Stat. Brief No. 177, Agency Healthc. Res. Quality (AHRQ), Rockville, MD. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb177-Hospitalizations-for-Opioid-Overuse.pdf
  57. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. 57.  2012. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000–2009. JAMA 307:1934–40 [Google Scholar]
  58. Paulozzi LJ. 58.  2010. The epidemiology of drug overdoses in the United States Presented at Promis. Leg. Responses to the Epidemic of Prescr. Drug Overdoses in the U.S., Maimonides Med. Cent. Dep. Psychiatry, Dec. 2, Grand Rounds, Brooklyn
  59. Perry S, Heidrich G. 59.  1982. Management of pain during debridement: a survey of U.S. burn units. Pain 13:267–80 [Google Scholar]
  60. Portenoy RK. 60.  1996. Opioid therapy for chronic nonmalignant pain: clinicians' perspective. J. Law Med. Ethics 24:296–309 [Google Scholar]
  61. Portenoy RK, Foley KM. 61.  1986. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain 25:171–86 [Google Scholar]
  62. Porter J, Jick H. 62.  1980. Addiction rare in patients treated with narcotics. N. Engl. J. Med. 302:123 [Google Scholar]
  63. Reif S, George P, Braude L, Dougherty RH, Daniels AS. 63.  et al. 2014. Residential treatment for individuals with substance use disorders: assessing the evidence. Psychiatr. Serv. 65:301–12 [Google Scholar]
  64. 64. SAMHSA (Substance Abuse Ment. Health Serv. Adm.) 2003. Results from the 2002 National Survey on Drug Use and Health: National Findings Off. Appl. Stud., NHSDA Ser. H-22, DHHS Publ. No. SMA 03-3836. Rockville, MD: SAMHSA
  65. 65. SAMHSA (Subst. Abuse Ment. Health Serv. Adm.) 2009. Trends in Nonmedical Use of Prescription Pain Relievers: 2002 to 2007 NSDUH Rep. Rockville, MD: SAMHSA
  66. 66. SAMHSA (Subst. Abuse Ment. Health Serv. Adm.) 2010. Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2007. Discharges from Substance Abuse Treatment Services . DASIS Ser.: S-51, HHS Publ. No. (SMA) 10-4479. Rockville, MD: SAMHSA [Google Scholar]
  67. 67. SAMHSA (Subst. Abuse Ment. Health Serv. Adm.) 2011. CAI Specifications for Programming in English: 2012 National Survey on Drug Use and Health Rockville, MD: SAMHSA https://www.icpsr.umich.edu/icpsrweb/DSDR/studies/34933?keyword%5B0%5D=drug+dependence&q=ANLNDMOR&=groupResults=false
  68. 68. SAMHSA (Subst. Abuse Ment. Health Serv. Adm.) 2013. Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2001–2011. National Admissions to Substance Abuse Treatment Services BHSIS Ser. S-65, DHHS Publ. No. SMA 13-4772. Rockville, MD: SAMHSA [Google Scholar]
  69. 69. SAMHSA (Subst. Abuse Ment. Health Serv. Adm.) 2013. Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits DHHS Publ. No. SMA 13-4760, DAWN Ser. D-39. Rockville, MD: SAMHSA
  70. 70. SAMHSA (Subst. Abuse Ment. Health Serv. Adm.) 2013. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings NSDUH Ser. H-46, DHHS Publ. No. SMA 13-4795. Rockville, MD: SAMHSA
  71. Saunders KW, Dunn KM, Merrill JO, Sullivan MD, Weisner CM. 71.  et al. 2010. Relationship of opioid use and dosage levels to fractures in older chronic pain patients. J. Gen. Intern. Med. 25:310–15 [Google Scholar]
  72. Schwartz RP, Gryczynski J, O'Grady KE, Sharfstein JM, Warren G. 72.  et al. 2013. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. Am. J. Public Health 103:917–22 [Google Scholar]
  73. Seal KH, Thawley R, Gee L, Bamberger J, Kral AH. 73.  et al. 2005. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J. Urban Health 82:303–11 [Google Scholar]
  74. Sees KL, Delucchi KL, Masson C, Rosen A, Clark HW. 74.  et al. 2000. Methadone maintenance for opioid dependence. JAMA 284:694–95 [Google Scholar]
  75. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. 75.  1999. Moderate versus high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 281:1000–5 [Google Scholar]
  76. Sullivan MD, Von Korff M, Banta-Green C, Merrill JO, Saunders K. 76.  2010. Problems and concerns of patients receiving chronic opioid therapy for chronic non-cancer pain. Pain 149:345–53 [Google Scholar]
  77. Takkouche B, Montes-Martínez A, Gill SS, Etminan M. 77.  2007. Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf. 30:171–84 [Google Scholar]
  78. Thomas CP, Kim M, Nikitin RV, Kreiner P, Clark TW, Carrow GM. 78.  2014. Prescriber response to unsolicited prescription drug monitoring program reports in Massachusetts. Pharmacoepidemiol. Drug Saf. 23:950–57 [Google Scholar]
  79. Thomson MW, Poulton R, Broadbent MJ, Al-Kubaisy S. 79.  2006. Xerostomia and medications among 32-year-olds. Acta. Odontol. Scand. 64:249–54 [Google Scholar]
  80. Turk DC, Brody MC, Okifuji EA. 80.  1994. Physicians' attitudes and practices regarding the long-term prescribing of opioids for non-cancer pain. Pain 59:201–8 [Google Scholar]
  81. Tuteja AK, Biskupiak J, Stoddard GJ, Lipman AG. 81.  2010. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol. Motil. 22:424–30 [Google Scholar]
  82. 82. US Drug Enforc. Admin. (DEA) 2014. Disposal of controlled substances. Fed. Regist. 79:17453520–70 [Google Scholar]
  83. Upadhyay J, Maleki N, Potter J, Elman I, Rudrauf D. 83.  et al. 2010. Alterations in brain structure and functional connectivity in prescription opioid-dependent patients. Brain 133:2098–114 [Google Scholar]
  84. 84. US FDA (Food Drug Admin.) 2011. Comment from Physicians for Responsible Opioid Prescribing on the Food and Drug Administration (FDA) Notice: Draft blueprint for prescriber education; availability: long-acting/extended-release opioid class-wide risk evaluation and mitigation strategy Phys. Responsib. Opiod Prescr. (PROP), FDA-2011-D-0771-0069, Regulations.gov, Washington, DC. http://www.regulations.gov/#!documentDetail;D=FDA-2011-D-0771-0069 [Google Scholar]
  85. 85. US FDA (Food Drug Admin.) 2013. Guidance for Industry: Abuse-Deterrent Opioids—Evaluation and Labeling Silver Spring, MD: US FDA http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf
  86. 86. US GAO (Gen. Account. Off.) OxyContin Abuse and Diversion and Efforts to Address the Problem GAO-04-110. Washington, DC: GAO. http://www.gao.gov/new.items/d04110.pdf
  87. Volkow ND, Frieden TR, Hyde PS, Cha SS. 87.  2014. Medication-assisted therapies—tackling the opioid-overdose epidemic. N. Engl. J. Med. 370:2063–6 [Google Scholar]
  88. Vuong C, Van Uum SH, O'Dell LE, Lutfy K, Friedman TC. 88.  2010. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr. Rev. 31:98–132 [Google Scholar]
  89. 89. White House ONDCP (Off. Natl. Drug Control Policy) 2014. National Drug Control Strategy Washington, DC: ONDCP http://www.whitehouse.gov/sites/default/files/ndcs_2014.pdf
  90. Williams AV, Marsden J, Strang J. 90.  2014. Training family members to manage heroin overdose and administer naloxone: randomized trial of effects on knowledge and attitudes. Addiction 109:250–59 [Google Scholar]
  91. Younger JW, Chu LF, D'Arcy NT, Trott KE, Jastrzab LE, Mackey SC. 91.  2011. Prescription opioid analgesics rapidly change the human brain. Pain 152:1803–10 [Google Scholar]
/content/journals/10.1146/annurev-publhealth-031914-122957
Loading
/content/journals/10.1146/annurev-publhealth-031914-122957
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error